(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Deciphera Pharmaceuticals, LLC
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Novartis
Blueprint Medicines Corporation
Stanford University
Novartis
Adelphi Values LLC
M.D. Anderson Cancer Center